Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

2018 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia​
Hüttenrauch, M.; Ogorek, I.; Klafki, H.; Otto, M.; Stadelmann, C. ; Weggen, S. & Wiltfang, J. et al.​ (2018) 
Acta Neuropathologica Communications6(1) art. 108​.​ DOI: 

Documents & Media

40478_2018_Article_612.pdf5.89 MBAdobe PDFSupplementary information233.5 kBAdobe PDFSupplementary information153.83 kBAdobe PDFSupplementary information434.69 kBAdobe PDFSupplementary information285.14 kBAdobe PDFSupplementary information30.87 kBAdobe PDFSupplementary information481.99 kBAdobe PDFSupplementary information121.18 kBAdobe PDFSupplementary information207.38 kBAdobe PDFSupplementary information190.92 kBAdobe PDFSupplementary information106.04 kBAdobe PDFs40478-018-0612-3.pdf5.84 MBAdobe PDFdocument.pdf5.89 MBAdobe PDF


Published Version

Attribution 3.0 CC BY 3.0


Hüttenrauch, Melanie; Ogorek, Isabella; Klafki, Hans; Otto, Markus; Stadelmann, Christine ; Weggen, Sascha; Wiltfang, Jens; Wirths, Oliver 
Abstract Alzheimer’s disease (AD) is an irreversible, devastating neurodegenerative brain disorder characterized by the loss of neurons and subsequent cognitive decline. Despite considerable progress in the understanding of the pathophysiology of AD, the precise molecular mechanisms that cause the disease remain elusive. By now, there is ample evidence that activated microglia have a critical role in the initiation and progression of AD. The present study describes the identification of Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel AD-related factor in both transgenic mice and sporadic AD patients by expression profiling, immunohistochemistry and ELISA measurements. We show that GPNMB levels increase in an age-dependent manner in transgenic AD models showing profound cerebral neuron loss and demonstrate that GPNMB co-localizes with a distinct population of IBA1-positive microglia cells that cluster around amyloid plaques. Our data further indicate that GPNMB is part of a microglia activation state that is only present under neurodegenerative conditions and that is characterized by the up-regulation of a subset of genes including TREM2, APOE and CST7. In agreement, we provide in vitro evidence that soluble Aβ has a direct effect on GPNMB expression in an immortalized microglia cell line. Importantly, we show for the first time that GPNMB is elevated in brain samples and cerebrospinal fluid (CSF) of sporadic AD patients when compared to non-demented controls. The current findings indicate that GPNMB represents a novel disease-associated marker that appears to play a role in the neuroinflammatory response of AD.
Issue Date
Acta Neuropathologica Communications 
Klinik für Psychiatrie und Psychotherapie ; Institut für Neuropathologie ; Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) 



Social Media